This Biotech Catapults 70% Higher On Depression Drug Results - Investor's Business Daily

Investor's Business DailyThis Biotech Catapults 70% Higher On Depression Drug ResultsInvestor's Business DailyMatteis noted the difference of benefit for SAGE-217 is "both larger — and attained faster — than what's observed for other antidepressants today." He calls SAGE-217 a potential game-changer in treating depression. SAGE-217 works by modulating ...Sage Shares Soar Again As Depression Drug Hits Mark in Phase 2 TestXconomyall 154 news articles »